Innovent Biologics, Inc. (1801.HK) HKSE

Currency In HKD

Key Executives

Name	Title	Pay	Year Born
De-Chao Yu	Co-Founder, Chairman & Chief Executive Officer	49.49M	1964
Qian Zhang	Chief Commercial Officer, General Manager & Executive Director	4.88M	1987
Hao Xi Ede	Executive Director & Fund Managing Partner	8.08M	1959
Cong Ding	General Counsel	0	N/A
Hui Zhou	Chief R&D Officer for Oncology	0	N/A
Min Liu	Chief Commercial Officer	0	1973
Fei You	Chief Financial Officer	0	1979
Zhengwei Song	Director of IR & Financial Strategy	0	N/A
Kaisong Zhou	Chief Operating Officer	0	N/A
Raj Dhodda	Senior Vice President	0	N/A
Samuel Suhua Zhang	Global Chief Business Officer	0	1968
Blake Salisbury	Senior Vice President	0	N/A

Name

Title

Pay

Year Born

De-Chao Yu

Co-Founder, Chairman & Chief Executive Officer

49.49M

1964

Qian Zhang

Chief Commercial Officer, General Manager & Executive Director

4.88M

1987

Hao Xi Ede

Executive Director & Fund Managing Partner

8.08M

1959

Cong Ding

General Counsel

N/A

Hui Zhou

Chief R&D Officer for Oncology

N/A

Min Liu

Chief Commercial Officer

1973

Fei You

Chief Financial Officer

1979

Zhengwei Song

Director of IR & Financial Strategy

N/A

Kaisong Zhou

Chief Operating Officer

N/A

Raj Dhodda

Senior Vice President

N/A

Samuel Suhua Zhang

Global Chief Business Officer

1968

Blake Salisbury

Senior Vice President

N/A

Description

Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.